Stock Ratings / Health Care / TELO / dividends

TENX (39) MAIA (48) MNOV (30) LFVN (76) ⌘ Pro Terminal →

Telomir Pharmaceuticals Inc. (TELO) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Where is TELO trading relative to its 50-day, 200-day, and 52-week technical levels?

TELO last traded at $0.94 (-3.01% on volume of 96,701 shares), positioning the stock -16.81% below its 50-day simple moving average ($1.13) and -22.95% below its 200-day simple moving average ($1.22). Across its 52-week range of $0.79 to $1.58, TELO sits at the 19.0% percentile with a 14-day RSI of 29.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.06).

Q: Does TELO pay a dividend and is it safe?

Telomir Pharmaceuticals Inc. (TELO) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$0.94 -3.01% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.93

Telomir Pharmaceuticals Inc. (TELO) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $71.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TELO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TELO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Telomir Pharmaceuticals Inc. (NASDAQ: TELO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.94 (-3.01% 1D, market cap $71.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TELO ranks #716 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TELO compare to TENX and MAIA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TELO carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TENX (Tenax Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $69.6M) and MAIA (MAIA Biotechnology Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $72.9M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while LFVN leads on capital efficiency (29.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TELO?

▼

Per TELO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001971532), Telomir Pharmaceuticals Inc. generated $0 in revenue, -$10.4M in net income, and -$3.7M in free cash flow against $7.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.93 (-0.73%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TELO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY TELO SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 19% of 52W Range • RSI-14 at 29.3 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.12-6.3% Next Q

Q2 (-2Q)

Grade E$1.05-6.7% Next Q

Q3 (-1Q)

Grade E$0.98-4.1% Next Q

Current

Grade E$0.94-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TELO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TELO currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.13) and Max Pain ($0.99) forces dealer call-delta covering toward $1.66.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TELO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TELO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TELO)

✓Walkthrough of TELO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TELO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -32.86%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.96H $0.99L $0.79C $0.94VOL 96.7K

RES: $1.71SUP: $0.91SMA50: $1.13SMA200: $1.22

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TELO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TELO Butterfly Map → + Track TELO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TELO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TELO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TELO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TELO)

Health Care Rank #716 of 1016 ⚔️ TENX vs TELO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TELO vs. TENX, MAIA, MNOV, LFVN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Telomir Pharmaceuticals Inc. (TELO) ranks #716 by composite RQD confidence (34/100, grade E) and #704 by equity capitalization ($71.0M). Within this direct 5-issuer industry benchmark cohort, MNOV leads on earnings valuation at 5.7x trailing P/E, while LFVN leads on capital efficiency and profitability with 29.2% ROIC and 80.4% gross margin. LFVN currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with TELO at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TELO ACTIVE Telomir Pharmaceuticals Inc.	E	34/100	—	—	-35.0%	-3.01%	$71.0M	Benchmark Subject
TENX Tenax Therapeutics Inc.	D-	39/100	—	—	-35.0%	-3.76%	$69.6M	/tenx-vs-telo →
MAIA MAIA Biotechnology Inc.	D	48/100	—	—	-35.0%	-6.78%	$72.9M	/maia-vs-telo →
MNOV Medicinova Inc	E	30/100	5.7x	—	-35.0%	0.00%	$68.9M	/mnov-vs-telo →
LFVN Lifevantage Corporation (Delaware)	B+	76/100	7.5x	80.4%	29.2%	+0.17%	$73.9M	/lfvn-vs-telo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001971532

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Telomir Pharmaceuticals Inc. (TELO) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$10.4M, operating cash flow of -$3.7M, and free cash flow of -$3.7M (+27.3% YoY). On the balance sheet, TELO closed FY2025 with $7.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$10.4M	-$3.7M	-$3.7M	$7.3M	—
FY2024 (FY)	2024-12-31	$0	-$16.5M	-$5.1M	-$5.1M	$1.3M	—
FY2023 (FY)	2023-12-31	$0	-$13.1M	-$3.9M	-$3.9M	—	—

3. TELO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TELO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does TELO compare to TENX and MAIA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for TELO?

Where is TELO trading relative to its 50-day, 200-day, and 52-week technical levels?

TELO last traded at $0.94 (-3.01% on volume of 96,701 shares), positioning the stock -16.81% below its 50-day simple moving average ($1.13) and -22.95% below its 200-day simple moving average ($1.22). Across its 52-week range of $0.79 to $1.58, TELO sits at the 19.0% percentile with a 14-day RSI of 29.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.06).

TELO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does TELO pay a dividend and is it safe?

Telomir Pharmaceuticals Inc. (TELO) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: TELO RQD Cockpit TELO 12M Forecast TELO Earnings & Move TELO Dividends & DRIP TELO Insiders & 13F TELO Whale Options TELO Profit Sankey TELO News & Why

ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

TELO — Telomir Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: roarable-bundle-v1

As of: 2026-11-02T15:08:05Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, Telomir Pharmaceuticals Inc. (TELO) carries a composite score of 34 / 100 (E — Roarable Strong Sell — Forensic Risk / Avoid).\n- Fundamental Cash Engine (6 / 20): Return on invested capital (ROIC) registers at -35.0% with a free cash flow yield of -5.19% and gross margin of 0.0%.\n- Institutional 13F Whale Flow (7 / 20): Tracks institutional accumulation and dark-pool/options positioning relative to the Biotechnology: Pharmaceutical Preparations cohort.\n- Insider & Congressional Conviction (3 / 20): Evaluates open-market Form 4 executive purchases and Congressional PTR disclosures.\n- Macro Regime Fit (8 / 20): Equity beta of 1.00 across the Health Care sector.\n- Forensic Balance-Sheet Shield (10 / 20): Altman Z-Score of 2.50, Piotroski F-Score of 3/9, and Debt-to-Equity of 0.50.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %	\n	---	---	---	---	---	---	---	---	---	---	\n	$0.94	$71.0M	N/A	N/A	N/A	N/A	0.00%	1.00	$0.79 - $1.58	-35.0%

Business & Sector Positioning

Telomir Pharmaceuticals Inc. (TELO) is a NASDAQ-listed Health Care issuer operating in Biotechnology: Pharmaceutical Preparations with a market capitalization of $0.1B.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Operating within Biotechnology: Pharmaceutical Preparations (Health Care), TELO exhibits an operating margin of 0.0% and net margin of 0.0%. Prospective investors should monitor 2nd-order capex cycles, input cost pass-through in gross margin (0.0%), and valuation discipline (current multiple) relative to free cash flow conversion.

Open Questions for Prospective Investors

How sustainable is TELO's current operating margin (0.0%) and ROIC (-35.0%) over the next four quarters?\n2. Does the current valuation multiple (current EV/EBITDA) adequately discount macro sensitivity (Beta 1.00) in Biotechnology: Pharmaceutical Preparations?\n3. Will upcoming quarterly cash flow conversion support continued balance-sheet strength (Altman Z 2.50)?

TELO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Telomir Pharmaceuticals Inc. (TELO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TELO Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 27d ago

Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company

Common Stock PIPE Strengthens Telomir’s Capital Position as Company Advances Telomir-Zn into Clinical Development Under FDA-Cleared IND in Triple-Negative Breast Cancer (TNBC)MIAMI, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telo

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 46d ago

Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)

Findings Strengthen Telomir-Zn’s Oncology-Focused Platform While Demonstrating Broader Relevance of Its Metal-Dependent Epigenetic BiologyMIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ: T

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 140d ago

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

Insulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose Metabolism and Insulin Sensitivity and Further Validating Telomir-Zn's Metal-Homeostasis Mechanism Across Multiple Disea

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 192d ago

Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)

Transaction establishes global ownership rights of lead program and includes initial capital funding with additional optional milestone-based capital support aligned with key clinical milestones. MIAMI, FL / ACCESS Newsw

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 166d ago

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease

Study Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Reduced Hepatic Copper Burden, Improved Liver Biomarkers, and Reduced Tissue Degeneration in a Preclinical Wilson's Disease

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 216d ago

Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer

First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a favorable GLP safety profile. MIAMI, FL / ACCESS Newswire / March 31, 2026 /Telomir Pharmaceuticals, In

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 49d ago

Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models

Preclinical Findings Support Parallel Development Pathway in Canine Osteosarcoma as TNBC Program Advances Toward Site InitiationMIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a cli

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 84d ago

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

Iron-Rescue Experiments Confirm Iron-Dependent Mechanism. Tumor Suppressor Gene Reactivation and Anti-Tumor and Anti-Metastatic Activity Across Multiple Models.MIAMI, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuti

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TELO Bull vs. Bear Conversation Board — What's Your Call at $0.94?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TELO 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.84 (-12.5%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is TELO (E • RQD 34/100) a Buy at $0.96?

Welcome to the TELO (Telomir Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 34/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.81 (-15.6%)

Spot @ $0.96

Pump the brakes on TELO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on TELO, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Telomir Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.14 (+18.7%)

Spot @ $0.96

TELO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on TELO, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.96 (52-wk range $0.90 - $1.11), any beat on forward guidance forces shorts and underweight funds to chase.